Searchable abstracts of presentations at key conferences in endocrinology

ea0029p1281 | Obesity | ICEECE2012

Morbid child obesity-possible Rohhadnet syndrome: case report

Valea A. , Silaghi A. , Paul A. , Duncea I.

Introduction: ROHHADNET syndrome is a newly described condition characterized by rapid-onset obesity, pulmonary hypoventilation, hythalamic, autonomic dysregulation and, neural tumors. The severity of the clinical manifestations can rapidly lead to death by cardiorespiratory arrest.Case report: We present the case of a 5.10 years old girl, who was admitted in the Endocrinology department for evaluation of a significant weight gain began 2.5 years ago.</p...

ea0026p372 | Thyroid (non cancer) | ECE2011

Complications after thyroidectomy: a 10 years experience in a District General Hospital

Jafferbhoy S , Ramus N I

Background: Patients undergoing thyroid surgery are consented for a 1% risk of permanent hypocalcaemia and voice changes. These complications are considered to be permanent if they persist for more than 6 months. The aim of this study is to determine the incidence of complications in patients undergoing thyroid surgery in our hospital.Methods: From January 1999 to March 2009, all patients who underwent thyroid surgery under the care of one surgeon were i...

ea0026p399 | Thyroid (non cancer) | ECE2011

Faster response to cholestyramine added in treatment of patients with hyperthyroidism

Bonapart I E , Boumpaki A , Stamataki A

Introduction: Faster decline in serum thyroid hormone levels in hyperthyroidism is seen adding cholestyramine at conventional treatment in some studies (1.2).Design/methods: Retrospective controlled study. Follow-up: ±3 weeks.Patients with hyperthyroidism: 17 treated with antithyroid drugs (mean dose 35 mg/day) combined with cholestyramine (mean dose 12 g/day).Control group: 23 only treated with antithyr...

ea0026p576 | Cardiovascular endocrinology and lipid metabolism | ECE2011

Parathormone 1-84 in type 2 diabetic patients

Belovici M I , Buysschaert M

Objective: Increasing evidence suggests a role for mineral metabolism in cardio-vascular disease risk. We aimed at determining in type 2 diabetes patients the relationship between serum levels of 1–84 parathormone (PTH1–84), 25-hydroxy-vitamin D (25(OH)D) or calcium and the glycated hemoglobin (HbA1c), insulin sensitivity or β-cells function, but also the relationship between these factors and coronary arterial disease confirmed by myocardial scintigraphy.<p...

ea0026p611 | Clinical case reports | ECE2011

Remind familial hypocalciuric hypercalcemia as a cause of elevated parathyroid hormone and serum calcium: 5 patients

Bonapart I E , Boumpaki A , Stamataki A

Introduction: Familial hypocalciuric hypercalcemia (FHH) is a benign disorder, with inappropriately elevated parathyroid hormone, without the complications of hypercalcemia (1). It is important to discriminate FHH from primary hyperparathyroidism (PHPT), because of the consequences on symptomatic disease and therapeutic approach. Ca/Cr clearance ratio will be <0.01 in FHH and most often >0.02 in PHPT (2). In patients with PHPT and vitamin D deficiency, low urinary calc...

ea0026p702 | Diabetes complications | ECE2011

Matrix γ-carboxyglutamate (Gla) protein (MGP) in type 2 diabetes

Belovici M I , Buysschaert M

Objective: Matrix γ-carboxyglutamate (Gla) protein (MGP) is a marker of athero-sclerosis reflecting the degree of inhibition of ongoing calcification processes in the vascular wall. Osteoprotegerin (OPG) and adiponectin (ADP) exerts anti-inflammatory and anti-atherosclerotic effects. We aimed at determining in type 2 diabetes patients the relationship between serum MGP, OPG, ADP levels and the HbA1c, HOMA insulin-sensitivity or B-cell function.Resea...

ea0019p224 | Pituitary | SFEBES2009

Cloning and expression of calcium/calmodulin-dependent protein kinase ii isoforms in the developing zebrafish (Danio rerio)

Chand A , McGonnell I , Fowkes R

The family of calcium/calmodulin-dependent protein kinases (CaMK) are major effectors of calcium binding proteins in virtually all systems. Recently, CaMKs have been implicated in regulating pituitary and hypothalamic gene transcription to control the expression of gonadotrophin hormones and adrenocorticotrophin in the pituitary, and as a pivotal protein in the satiety pathway. Despite these observations, the spatial and temporal expression of the CaMKs is poorly documented an...

ea0012s17 | Cell-cell interactions in the regulation of endocrine cell function | SFE2006

Somatotrophs and lactotrophs: their regulation and communication

Robinson I , Le Tissier P

Pituitary hormones are released into the bloodstream in a pulsatile fashion in response to stimuli from their hypothalamic regulators. For efficient generation of hormone pulses, both the hypothalamic mechanisms and the pituitary target cells must exhibit a high degree of coordinated secretory activity. This is particularly important for the growth hormone (GH) axis since the target tissue responses are critically dependent on the temporal pattern of GH exposure, as well as th...

ea0005p199 | Reproduction | BES2003

Treatment of hypogonadotropic hypogonadism in women with neuroendocrine disorders

Ilovaiskaia I , Pischulin A , Marova E

We observed 26 women from 19 to 40 years old (mean age 27) with hypogonadotropic hypogonadism (HH) due to different causes excluding prolactinomas. The continuance of HH was from 1 to 23 years (mean 6 years 4 months). Main complains were amenorrhea (all patients), urogenital disorders (18 patients), ingravescent memory and fatigue (17 patients). Biochemical blood test relieved increased cholesterol and high density lipoprotein levels in all patients, increased triglyceride lev...

ea0073aep261 | Diabetes, Obesity, Metabolism and Nutrition | ECE2021

Self-Management Behavior of the Patients with Type 2 Diabetes: A Cross-Sectional Survey in the Eastern European population (Belarus)

Yaroma Andrei , Danilova Larissa I.

BackgroundThe prevention of complications and improvement of metabolic control and state of health in diabetes cannot be effective only with medications. And now we need to develop different approaches – not only up to date pharmacological treatment of diabetes, but change the Self-Management Behavior among patients with Type 2 Diabetes.AimsTo assess the current status of diabetic self-management behavio...